Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Hybrid histidine kinase activation by cyclic di-GMP-mediated domain liberation.

Dubey BN, Agustoni E, Böhm R, Kaczmarczyk A, Mangia F, von Arx C, Jenal U, Hiller S, Plaza-Menacho I, Schirmer T.

Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1000-1008. doi: 10.1073/pnas.1911427117. Epub 2019 Dec 27.


Novel targeted therapeutics for MEN2.

Redaelli S, Plaza-Menacho I, Mologni L.

Endocr Relat Cancer. 2018 Feb;25(2):T53-T68. doi: 10.1530/ERC-17-0297. Review.


Structure and function of RET in multiple endocrine neoplasia type 2.

Plaza-Menacho I.

Endocr Relat Cancer. 2018 Feb;25(2):T79-T90. doi: 10.1530/ERC-17-0354. Epub 2017 Nov 24. Review.


RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements.

Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ.

Cell Rep. 2016 Dec 20;17(12):3319-3332. doi: 10.1016/j.celrep.2016.11.061.


Cyclic di-GMP mediates a histidine kinase/phosphatase switch by noncovalent domain cross-linking.

Dubey BN, Lori C, Ozaki S, Fucile G, Plaza-Menacho I, Jenal U, Schirmer T.

Sci Adv. 2016 Sep 16;2(9):e1600823. doi: 10.1126/sciadv.1600823. eCollection 2016 Sep.


Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

Plaza-Menacho I, Mologni L, McDonald NQ.

Cell Signal. 2014 Aug;26(8):1743-52. doi: 10.1016/j.cellsig.2014.03.032. Epub 2014 Apr 3. Review.


Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans.

Plaza-Menacho I, Barnouin K, Goodman K, Martínez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P, McDonald NQ.

Mol Cell. 2014 Mar 6;53(5):738-51. doi: 10.1016/j.molcel.2014.01.015. Epub 2014 Feb 20.


Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C.

Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. Epub 2013 Jun 27.


GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM.

Cancer Res. 2013 Jun 15;73(12):3783-95. doi: 10.1158/0008-5472.CAN-12-4265. Epub 2013 May 6.


Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.

Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM.

J Biol Chem. 2011 May 13;286(19):17292-302. doi: 10.1074/jbc.M110.168500. Epub 2011 Mar 22.


RET in breast cancer: functional and therapeutic implications.

Morandi A, Plaza-Menacho I, Isacke CM.

Trends Mol Med. 2011 Mar;17(3):149-57. doi: 10.1016/j.molmed.2010.12.007. Epub 2011 Jan 19. Review.


Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM.

Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7.


A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.

Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, Reis-Filho JS, Isacke CM.

Cancer Res. 2007 Dec 15;67(24):11732-41.


Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.

Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM.

J Biol Chem. 2007 Oct 5;282(40):29230-40. Epub 2007 Jul 30.


Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.

Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, Isacke CM, Hofstra RM, Eggen BJ.

J Biol Chem. 2007 Mar 2;282(9):6415-24. Epub 2007 Jan 5.


Current concepts in RET-related genetics, signaling and therapeutics.

Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM.

Trends Genet. 2006 Nov;22(11):627-36. Epub 2006 Sep 18. Review.


Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.

de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, Links TP, Eggen BJ, Hofstra RM.

Surgery. 2006 Jun;139(6):806-14.


Identifying candidate Hirschsprung disease-associated RET variants.

Burzynski GM, Nolte IM, Bronda A, Bos KK, Osinga J, Plaza Menacho I, Twigt B, Maas S, Brooks AS, Verheij JB, Buys CH, Hofstra RM.

Am J Hum Genet. 2005 May;76(5):850-8. Epub 2005 Mar 9.


RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.

Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM.

Cancer Res. 2005 Mar 1;65(5):1729-37.


Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2.

Burzynski GM, Nolte IM, Osinga J, Ceccherini I, Twigt B, Maas S, Brooks A, Verheij J, Plaza Menacho I, Buys CH, Hofstra RM.

Eur J Hum Genet. 2004 Aug;12(8):604-12.


Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors".

Plaza Menacho I, de Groot JW, Links T, Plukker J, Eggen BJ, Hofstra R.

Surgery. 2004 Feb;135(2):240-1; author reply 241. No abstract available.


Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target.

Komdeur R, Hoekstra HJ, Molenaar WM, Van Den Berg E, Zwart N, Pras E, Plaza-Menacho I, Hofstra RM, Van Der Graaf WT.

Clin Cancer Res. 2003 Aug 1;9(8):2926-32.

Supplemental Content

Loading ...
Support Center